Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
”Thank you EHTG – European Hereditary Tumour Group for a fantastic meeting and for the opportunity to present our Dana-Farber Cancer Institute data about Overall Survival of Individuals with Pancreatic Cancer Harboring Pathogenic Germline Variants in BRCA1, BRCA2, PALB2 and ATM.”
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
